Tags

Type your tag names separated by a space and hit enter

Differential action of methylselenocysteine in control and alloxan-diabetic rabbits.
Chem Biol Interact. 2009 Jan 27; 177(2):161-71.CB

Abstract

Antidiabetic action of inorganic selenium compounds is commonly accepted. Since in diet selenium mainly exists as selenoamino acids, potential hypoglycemic properties of methylselenocysteine (MSC) were investigated in four groups of rabbits: untreated and MSC-treated control animals as well as alloxan-diabetic and MSC-treated diabetic rabbits. MSC (at a dose of 1mg/kg body weight) was administered daily for 3 weeks via intraperitoneal injection. The data show, that in MSC-treated control animals plasma glucose concentration was diminished, while plasma urea and creatinine levels as well as urine albumin content were elevated and necrotic changes occurred in kidney-cortex. Decreased GSH/GSSG ratios in blood, liver and kidney-cortex were accompanied by increased glutathione peroxidase and glutathione reductase activities and a diminished renal gamma-glutamylcysteine synthetase activity. Death of 50% of control animals was preceded by a dramatic decline in blood glucose concentration. Surprisingly, in MSC-treated diabetic rabbits, plasma glucose levels were either normalized or significantly decreased. Blood and liver GSH/GSSG ratios were increased and renal functions were markedly improved, as indicated by a diminished albuminuria and attenuated histological changes characteristic of diabetes. However, after administration of MSC to diabetic rabbits plasma urea and creatinine levels as well as renal GSH/GSSG ratios were not altered. In view of MSC-induced marked accumulation of selenium in kidneys and liver of control rabbits, accompanied by a decline in blood glucose level, disturbance of glutathione homeostasis and kidney-injury, application of MSC in chemotherapy needs a careful evaluation. On the contrary, MSC supplementation might be beneficial for diabetes therapy due to an improvement of both glycemia and renal function.

Authors+Show Affiliations

Department of Metabolic Regulation, Institute of Biochemistry, Faculty of Biology, University of Warsaw, ul. Miecznikowa 1, 02-096 Warsaw, Poland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19010315

Citation

Kiersztan, Anna, et al. "Differential Action of Methylselenocysteine in Control and Alloxan-diabetic Rabbits." Chemico-biological Interactions, vol. 177, no. 2, 2009, pp. 161-71.
Kiersztan A, Baranska A, Hapka M, et al. Differential action of methylselenocysteine in control and alloxan-diabetic rabbits. Chem Biol Interact. 2009;177(2):161-71.
Kiersztan, A., Baranska, A., Hapka, M., Lebiedzinska, M., Winiarska, K., Dudziak, M., & Bryla, J. (2009). Differential action of methylselenocysteine in control and alloxan-diabetic rabbits. Chemico-biological Interactions, 177(2), 161-71. https://doi.org/10.1016/j.cbi.2008.10.022
Kiersztan A, et al. Differential Action of Methylselenocysteine in Control and Alloxan-diabetic Rabbits. Chem Biol Interact. 2009 Jan 27;177(2):161-71. PubMed PMID: 19010315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differential action of methylselenocysteine in control and alloxan-diabetic rabbits. AU - Kiersztan,Anna, AU - Baranska,Anna, AU - Hapka,Michal, AU - Lebiedzinska,Magdalena, AU - Winiarska,Katarzyna, AU - Dudziak,Marta, AU - Bryla,Jadwiga, Y1 - 2008/11/01/ PY - 2008/07/29/received PY - 2008/10/02/revised PY - 2008/10/06/accepted PY - 2008/11/18/pubmed PY - 2009/1/14/medline PY - 2008/11/18/entrez SP - 161 EP - 71 JF - Chemico-biological interactions JO - Chem Biol Interact VL - 177 IS - 2 N2 - Antidiabetic action of inorganic selenium compounds is commonly accepted. Since in diet selenium mainly exists as selenoamino acids, potential hypoglycemic properties of methylselenocysteine (MSC) were investigated in four groups of rabbits: untreated and MSC-treated control animals as well as alloxan-diabetic and MSC-treated diabetic rabbits. MSC (at a dose of 1mg/kg body weight) was administered daily for 3 weeks via intraperitoneal injection. The data show, that in MSC-treated control animals plasma glucose concentration was diminished, while plasma urea and creatinine levels as well as urine albumin content were elevated and necrotic changes occurred in kidney-cortex. Decreased GSH/GSSG ratios in blood, liver and kidney-cortex were accompanied by increased glutathione peroxidase and glutathione reductase activities and a diminished renal gamma-glutamylcysteine synthetase activity. Death of 50% of control animals was preceded by a dramatic decline in blood glucose concentration. Surprisingly, in MSC-treated diabetic rabbits, plasma glucose levels were either normalized or significantly decreased. Blood and liver GSH/GSSG ratios were increased and renal functions were markedly improved, as indicated by a diminished albuminuria and attenuated histological changes characteristic of diabetes. However, after administration of MSC to diabetic rabbits plasma urea and creatinine levels as well as renal GSH/GSSG ratios were not altered. In view of MSC-induced marked accumulation of selenium in kidneys and liver of control rabbits, accompanied by a decline in blood glucose level, disturbance of glutathione homeostasis and kidney-injury, application of MSC in chemotherapy needs a careful evaluation. On the contrary, MSC supplementation might be beneficial for diabetes therapy due to an improvement of both glycemia and renal function. SN - 1872-7786 UR - https://www.unboundmedicine.com/medline/citation/19010315/Differential_action_of_methylselenocysteine_in_control_and_alloxan_diabetic_rabbits_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-2797(08)00536-X DB - PRIME DP - Unbound Medicine ER -